ABVC BioPharma Inc. Common Stock (ABVC)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money today and can protect those earnings. ABVC BioPharma is not that. It is a clinical-stage biopharmaceutical company with 16 employees, and its filed results show losses, not durable profits. In fiscal 2025, the year ended 2025-12-31, revenue was $296,000 and net loss was $7.9 million, or $0.39 per diluted share. In fiscal 2024, net loss was $4.9 million, or $0.42 per diluted share, with revenue not reported. In fiscal 2023, revenue was $152,430 and net loss was $7.8 million, or $1.80 per diluted share. More recently, in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $736,934, or $0.03 per diluted share; in fiscal Q1 2026, net loss was $1.6 million, or $0.06 per diluted share. Those are not the marks of a business with pricing power or a moat. The FairStock calculations at the 2026-10-13 close of $0.98 show a market cap of $26.1 million, P/E of -3.38, P/B of 2.45, ROE of -69.86%, ROCE of -22.85%, and a free cash flow yield of -13.5%. Debt/equity of 0.24 is not alarming by itself, but trailing free cash flow is -$3.5 million, the Altman Z-score is -4.39, and the Piotroski F-score is 3/9. The FairStock Score is 30/100. Growth depends on clinical trials, not on revenue compounding. I can admire the science, but as a value investor I see no margin of safety in the numbers. The stock is a lottery ticket on trial data, and the price is not supported by current earnings or assets.

In plain English: ABVC BioPharma is a tiny clinical-stage drug and device company with 16 employees, working on experimental treatments in areas like breast cancer, depression, and ADHD. The business looks weak today because it has no steady revenue and keeps losing money. At about 98 cents a share as of the close on 2026-10-13, the price looks speculative and not clearly cheap compared with its losses and accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer